NCCM
CLDX icon

Nine Chapters Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Nine Chapters Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$90K Buy
+2,093
New +$78.5K 0.2% 126
2015
Q2 		– Sell
-3,453
Closed -$1.44M – 990
2015
Q1 		$1.44M Buy
+3,453
New +$1.24M 0.12% 243

Other funds holding CLDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nine Chapters Capital Management's CLDX Position: Q3 2017 in Review

Nine Chapters Capital Management opened a new position in Celldex Therapeutics (CLDX) in Q3 2017: 2,093 shares worth $90K. The stake represents 0.2% of the portfolio and ranks #126 among its holdings. This is a return to the name: Nine Chapters Capital Management previously reported a position in CLDX as recently as Q1 2015.

Nine Chapters Capital Management first reported a position in CLDX in Q1 2015 and has held it in 2 quarters since. The position peaked at $1.44M in Q1 2015. 129 funds tracked by Wall St. Rank hold CLDX as of Q3 2017.

  • Nine Chapters Capital Management held 2,093 shares of Celldex Therapeutics worth $90K as of Q3 2017.
  • Celldex Therapeutics was a new Nine Chapters Capital Management position in Q3 2017.
  • Celldex Therapeutics made up 0.2% of Nine Chapters Capital Management's portfolio in Q3 2017, its #126 holding.
  • Nine Chapters Capital Management first reported a position in Celldex Therapeutics in Q1 2015 and has held it in 2 quarters since.
  • Nine Chapters Capital Management's Celldex Therapeutics position peaked at $1.44M in Q1 2015.
  • 129 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2017.

Based on Nine Chapters Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.